【drug-news】【资讯翻译】“公共市民”团体就“爱忆欣”安全问题起诉FDA
这个帖子发布于 12 年零 293 天前，其中的信息可能已发生改变或有所发展。
http://www.fiercepharma.com/story/public-citizen-sues-fda-over-aricept-safety/2012-09-06
认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看：【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高
寻找最近的翻译贴请查看：http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分
Public Citizen has stepped up its fight against high-dose Aricept. The consumer advocacy group, which demanded last year that FDA pull the Eisai drug's 23 mg dose, sued the agency yesterday for action.
The lawsuit reiterates Public Citizen's claims about the Alzheimer's treatment--that Eisai's own data show that the higher dose isn't more effective at treating moderate to severe Alzheimer's. What it does offer, Public Citizen says, is a greater risk of side effects such as nausea, vomiting and gastric bleeding.
"Although the study failed to show that the 23 mg dose has any clinically meaningful benefit, the study demonstrated that, in comparison with the 10 mg dose, the use of a 23 milligram dose ... is associated with a significant risk to patient safety," the lawsuit claims (as quoted by Bloomberg).
As the news service points out, the 23 mg dose of Aricept won FDA approval in 2010, just as the 10 mg dose neared patent expiration. With 38% of its 2010 sales coming from Aricept, Eisai had every incentive to promote the newer dose. For the first half of its fiscal 2011, the first full period after generic rivals hit the market, Eisai's profits dropped by 17%, as Aricept revenues plummeted by more than half.
FDA wouldn't comment on the lawsuit, and nor would Pfizer ($PFE), which is Eisai's U.S. marketing partner. Eisai itself said it stands by its 23 mg Aricept product as a "safe and effective treatment of moderate to severe Alzheimer's disease."
认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看：【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高
寻找最近的翻译贴请查看：http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分
Public Citizen has stepped up its fight against high-dose Aricept. The consumer advocacy group, which demanded last year that FDA pull the Eisai drug's 23 mg dose, sued the agency yesterday for action.
The lawsuit reiterates Public Citizen's claims about the Alzheimer's treatment--that Eisai's own data show that the higher dose isn't more effective at treating moderate to severe Alzheimer's. What it does offer, Public Citizen says, is a greater risk of side effects such as nausea, vomiting and gastric bleeding.
"Although the study failed to show that the 23 mg dose has any clinically meaningful benefit, the study demonstrated that, in comparison with the 10 mg dose, the use of a 23 milligram dose ... is associated with a significant risk to patient safety," the lawsuit claims (as quoted by Bloomberg).
As the news service points out, the 23 mg dose of Aricept won FDA approval in 2010, just as the 10 mg dose neared patent expiration. With 38% of its 2010 sales coming from Aricept, Eisai had every incentive to promote the newer dose. For the first half of its fiscal 2011, the first full period after generic rivals hit the market, Eisai's profits dropped by 17%, as Aricept revenues plummeted by more than half.
FDA wouldn't comment on the lawsuit, and nor would Pfizer ($PFE), which is Eisai's U.S. marketing partner. Eisai itself said it stands by its 23 mg Aricept product as a "safe and effective treatment of moderate to severe Alzheimer's disease."
